RBI & SEBI
OneSource Specialty Pharma announces resignation of Chief Quality Officer Bernhard Thurnbauer
Originally reported by scanx.trade as: OneSource Specialty Pharma CQO Bernhard Thurnbauer resigns effective Nov 17
17 Nov 2026, 6:15 pm IST · Xecute.finance News DeskArchive edition
The crisp read
OneSource Specialty Pharma has announced the departure of its Chief Quality Officer, Bernhard Thurnbauer. His resignation takes effect on November 17. The update was reported via financial tracking platforms.
Xecute Impact Breakdown
For CAs
- Bernhard Thurnbauer has submitted his resignation as Chief Quality Officer of OneSource Specialty Pharma.
- The departure becomes effective on November 17.
- Compliance officers and stakeholders should monitor subsequent corporate filings for announcements regarding a replacement.
For businesses
- OneSource Specialty Pharma announced the resignation of its Chief Quality Officer, Bernhard Thurnbauer, effective November 17.
- The announcement does not detail immediate succession plans or the reasons behind the departure.
- Stakeholders and investors should keep a close watch on subsequent corporate filings for replacement announcements.
Effective November 17
Deep dive – the full story
OneSource Specialty Pharma has officially announced that its Chief Quality Officer (CQO), Bernhard Thurnbauer, has submitted his resignation. According to the disclosure, his departure from the company becomes effective on November 17. The announcement outlines the change in executive personnel without detailing immediate succession plans or the reasons behind the departure. In the pharmaceutical sector, the role of a Chief Quality Officer is critical for overseeing manufacturing standards, regulatory compliance, and quality control systems required by health authorities.
Changes in this leadership position draw attention because quality assurance directly impacts product approvals, manufacturing plant audits, and operational continuity. The transition from the outgoing officer to a successor represents a shift in top-level oversight for the firm's quality management protocols. Stakeholders, compliance officers, and investors should keep a close watch on subsequent corporate filings for announcements regarding a replacement for the Chief Quality Officer role.
Advertisement
Monitoring regulatory disclosures ensures that market participants remain informed about leadership continuity and compliance readiness. The bottom line is that executive changes in key quality control positions warrant careful observation by anyone tracking the operational stability of pharmaceutical entities.
Source: news.google.com
This is news/educational content, not investment advice. Xecute.finance is not SEBI-registered. Consult a qualified professional before acting.
Advertisement
More from the Xecute news desk
- Cong opposes SEBI's proposed review of FPI disclosure norms, warns of opaque foreign fund ownership
- Essential Business Framework for Managing Foreign Exchange Risks Under Reserve Bank of India Rules
- Reserve Bank of India projects 6.7% gross domestic product growth for fiscal year 2027
- Bank branches including SBI, HDFC and ICICI will remain closed on five days between November 23 and 30
Advertisement
Reading the archive edition.
This story has retired from the live feed - the full text stays here permanently. The live app adds the newest desk, Ask Xecute, deadline trackers and the daily quiz.
Open this story in the Xecute app →